NCT04585997View on ClinicalTrials.gov

"Comparing Treatment Efficacy With Mepolizumab and Omalizumab in Severe Asthma - Choosebetweenamab."

PHASE4UnknownINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

November 3, 2018

Primary Completion Date

June 30, 2022

Study Completion Date

December 31, 2022

Conditions
AsthmaEosinophilic Asthma
Interventions
DRUG

Mepolizumab

Mepolizumab 100mg subcutaneous injection monthly for 6 months

DRUG

Omalizumab

Omalizumab subcutaneous injection every 2-4 weeks (dosage determined by the Omalizumab nomogram).

Trial Locations (1)

2305

RECRUITING

John Hunter Hospital, New Lambton

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

University of Newcastle, Australia

OTHER

NCT04585997 - "Comparing Treatment Efficacy With Mepolizumab and Omalizumab in Severe Asthma - Choosebetweenamab." | Biotech Hunter | Biotech Hunter